Last updated: 2026-09-09 10:37:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MacroGenics, Inc. (MGNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.29, with a market capitalization of $280.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.29 to $5.08. This page covers its latest market performance, valuation, price trends and company information.
$280.28M | |
$4.34 | |
$41.00 | |
$0.99 | |
$4.32 | |
333.00 | |
850.50K | |
-- | |
$5.08 | |
$1.29 | |
-- | |
-- |
MacroGenics, Inc. (MGNX) is trading at $4.29 in pre-market trading as of 2026-09-09 10:14:00, down 0.79% ($0.03) from the previous close of $4.32
Pre-market trading shows how investors are pricing MGNX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, MacroGenics, Inc. (MGNX) moved from $4.13 to $4.29, representing a gain of 3.78% ($0.16).
The stock traded between $3.89 and $4.49 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 501.00 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 79.1%
MGNX is currently trading at $4.29, placing it 79.1% of the way from its 52-week low of $1.29 to its 52-week high of $5.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 293 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MacroGenics, Inc. (MGNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.